UY37869A - Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvir - Google Patents

Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvir

Info

Publication number
UY37869A
UY37869A UY0001037869A UY37869A UY37869A UY 37869 A UY37869 A UY 37869A UY 0001037869 A UY0001037869 A UY 0001037869A UY 37869 A UY37869 A UY 37869A UY 37869 A UY37869 A UY 37869A
Authority
UY
Uruguay
Prior art keywords
combination therapies
parapoxvir
vhb
hepatitis
viruses
Prior art date
Application number
UY0001037869A
Other languages
English (en)
Inventor
Ibironke Addy Dra
Daniela Paulsen Dra
Andreas Urban Dr
Stephan Menne Dr
Willem Sloot Dr
Tamara Pfaff Dra
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of UY37869A publication Critical patent/UY37869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a nuevas terapias de combinación de individuos infectados con VHB usando un Parapoxvirus ovis (PPVO) y al menos un fármaco antivírico adicional, por ejemplo, inhibidores de nucleósido, tales como Entecavir. Los métodos y los productos de combinación de acuerdo con la presente invención son seguros y adecuados para la inducción de una cura funcional en pacientes crónicamente infectados con VHB.
UY0001037869A 2017-09-07 2018-09-07 Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvir UY37869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189890 2017-09-07
EP17196684 2017-10-16

Publications (1)

Publication Number Publication Date
UY37869A true UY37869A (es) 2019-04-30

Family

ID=63442656

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037869A UY37869A (es) 2017-09-07 2018-09-07 Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvir

Country Status (20)

Country Link
US (1) US20200261520A1 (es)
EP (1) EP3678697A1 (es)
JP (2) JP2020533314A (es)
KR (1) KR20200051685A (es)
CN (1) CN111093697A (es)
AU (1) AU2018327688B2 (es)
BR (1) BR112020004539A2 (es)
CA (1) CA3075206A1 (es)
CL (1) CL2020000556A1 (es)
CU (1) CU20200016A7 (es)
EC (1) ECSP20016672A (es)
GE (1) GEP20237518B (es)
IL (1) IL273093A (es)
MA (1) MA50071A (es)
MX (1) MX2020002605A (es)
PH (1) PH12020500445A1 (es)
SG (1) SG11202001931WA (es)
TW (1) TW201919675A (es)
UY (1) UY37869A (es)
WO (1) WO2019048640A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
PT3906970T (pt) * 2020-05-08 2022-08-23 Aicuris Gmbh & Co Kg Parapoxvírus para condicionamento e tratamento de infeções por coronavírus
WO2021242850A1 (en) * 2020-05-28 2021-12-02 The Regents Of The University Of Michigan Compositions and methods for preventing and treating sars-cov-2 infection
WO2023083950A1 (en) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083943A1 (en) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083951A1 (en) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523535A (en) * 2000-07-11 2004-12-24 Bayer Ag Use of strains of the Parapoxvirus ovis against organ fibroses
SI21122A (sl) * 2000-07-11 2003-08-31 Bayer Aktiengesellschaft Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku
JP4897677B2 (ja) * 2004-07-13 2012-03-14 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト Ｈｉｖ／ａｉｄｓの処置用の他の抗ウイルス剤と組み合わせたパラポックスウイルス
EP1962841A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating virus infections
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
WO2017015451A1 (en) * 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents

Also Published As

Publication number Publication date
CA3075206A1 (en) 2019-03-14
PH12020500445A1 (en) 2020-11-09
MX2020002605A (es) 2020-07-20
EP3678697A1 (en) 2020-07-15
CL2020000556A1 (es) 2020-09-04
CN111093697A (zh) 2020-05-01
JP2020533314A (ja) 2020-11-19
CU20200016A7 (es) 2020-11-30
JP2022167901A (ja) 2022-11-04
ECSP20016672A (es) 2020-06-30
IL273093A (en) 2020-04-30
AU2018327688A1 (en) 2020-03-19
MA50071A (fr) 2020-07-15
AU2018327688B2 (en) 2022-12-01
WO2019048640A1 (en) 2019-03-14
TW201919675A (zh) 2019-06-01
SG11202001931WA (en) 2020-04-29
US20200261520A1 (en) 2020-08-20
BR112020004539A2 (pt) 2020-09-08
GEP20237518B (en) 2023-07-10
KR20200051685A (ko) 2020-05-13

Similar Documents

Publication Publication Date Title
ECSP20016672A (es) Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional
CY1123570T1 (el) Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20170174A (es) Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
PH12018550207A1 (en) Phosphoramidates for the treatment of hepatitis b virus
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
EA201890454A1 (ru) Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
BR112017000320A2 (pt) métodos para o tratamento de infecções virais de hepatite b e hepatite d
MX2017009812A (es) Composiciones y metodos para inhibir infeccion viral.
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
BR112015026243A2 (pt) método de inibição viral
EA201590297A1 (ru) Гетероциклические карбоксамиды для лечения вирусных заболеваний
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
EA202090597A1 (ru) Комбинированная терапия пациентов, инфицированных вирусом гепатита в (hbv), с использованием parapoxvirus ovis (ppvo) и по меньшей мере одного дополнительного противовирусного средства
AR112796A1 (es) Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional
MX2018000213A (es) Metodos para tratar el vhc.
AR105611A1 (es) TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110